LABStandard BioTools Inc.

$370M

Q4 2019 Earnings

Healthcare Medical - Devices

Income Statement

Revenue

$32M+0.4% YoY

Gross Profit

$18M55.1% margin

Operating Income

-$9M-28.3% margin

Net Income

-$13M-39.1% margin

EPS (Diluted)

$-0.18

QoQ Revenue Growth

+22.4%

Cash Flow

Operating Cash Flow

-$6M

Free Cash Flow

-$6M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$265M

Total Liabilities

$111M

Stockholders' Equity

$154M

Cash & Equivalents

$22M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$32M	$32M	+0.4%
Gross Profit	$18M	$19M	-4.9%
Operating Income	-$9M	-$11M	+17.4%
Net Income	-$13M	-$15M	+14.1%

Revenue Segments

Product

$27M45%

Instruments

$16M27%

Consumables

$11M18%

Service

$5M9%

Grant Revenue

$350,0001%

Geographic Segments

Americas

$12M57%

Asia Pacific

$9M43%

LAB Q4 2019 Earnings — Standard BioTools Inc. Revenue & Financial Results | Market Cap Arena